摘要
目的探讨自制金香丹片治疗冠心病心绞痛的作用及其机制。方法冠心病心绞痛患者316例,随机分为金香丹组172例,地奥心血康组(对照组)144例,疗程4周。比较治疗前后症状、心电图的变化,并通过动物实验观察其对大鼠血清一氧化氮(N0)、血浆内皮素(ET)、血浆前列环素(PGI2)、血栓烷素(TXA2)、血清丙二醛(MDA)、血清肌酸激酶(CK)水平的影响。结果金香丹组症状、心电图总有效率为83.1%、68.6%,地奥心血康组总有效率为80.6%、57.6%,心电图疗效经统计学处理有显著差异(P<0.05)。金香丹大剂量组较地奥心血康组CK、TXA2、MOA、ET浓度显著降低(P<0.01),N0、PGI2浓度明显升高(P<0.05或0.01)。电镜下心肌超微结构改变显示,金香丹大剂量组损伤最轻。结论金香丹是治疗冠心病心绞痛的有效药物,其机理与提高血浆PGI2、血清N0水平,降低血浆ET、TXA2及血清MDA水平有关。
Objective To explore the effect and mechanism of Jinxiangdan tablets in treating coronary heart disease (CHD) angina pectoris. Method 316 cases of CHD angina pectoris patients were divided into Jinxiangdan group (172 cases) and Diao Xinxuekang group (144 cases) at random. Treatment period lasted for four weeks. The change of symptom and ECG were compared before and after treatment. And observe it's influence on the level of serum NO, plasma ET, plasma PGI2, plasma TXA2, serum MDA, serum CK by the rat-experiment. Result The total effective rate of Jinxiangdan group symptom and ECG were 83.1% and 68.6% while the Diao Xinxuekang group were 80.6% and 57.6%. The treatment effect of ECG has significant difference (P <0.05). Compared with Diao Xinxuekang group, Jinxiangdan group's content of CK, TXA2, MDA, ET decreased significantly (P <0.01) while the content of NO, PGI2 increased significantly (P <0.05, P <0.01). The change of myocardial ultrastructures showed that the damage of Jinxiangdan group was the less. Conclusion Jinxiangdan is the effective drug of treating CHD angina pectoris. The mechanism has relation with elevating the level of PGI2, NO and deducing the level of ET, TXA2, MDA.
出处
《中国中医药信息杂志》
CAS
CSCD
2005年第6期6-9,共4页
Chinese Journal of Information on Traditional Chinese Medicine
基金
湖北省科技厅重点科技发展课题(鄂科技[2000]23号1B33)
